> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 28-Page FDA-483 for Edge Pharma Inspection
- URL: https://www.fdaweb.com/28-page-fda-483-for-edge-pharma-inspection/
- Published: 2022-02-23T12:00:00.000Z
- Updated: 2026-09-14T17:33:50.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151226

FDA has released a 28-page FDA-483 with 13 observations from a 9/20-11/30/21 inspection at Edge Pharma, a Colchester, VT, outsourcing facility. The inspection observations were: 

- buildings used in the manufacturing, processing, packing, and holding of a drug product are not maintained in a good state of repair;
- failing to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed;
- aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions;
- failing to write and follow test procedures relative to appropriate laboratory testing for sterility;
- failing to establish, write, and follow procedures designed to prevent microbiological contamination of drug products purporting to be sterile;
- aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions;
- buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable systems to facilitate cleaning, maintenance, and proper operations;
- failing to write and fully follow responsibilities and procedures applicable to the quality control unit;
- failing to perform routine calibration, inspection, and checking of automatic and mechanical equipment according to a written program designed to assure proper performance;
- failing to follow the written stability testing program;
- failure of the written stability program for drug products to include reliable and specific test methods;
- failing to exercise appropriate controls over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel; and
- the labels of the outsourcing facility’s drug products are deficient.

Many of the observations were repeated from one or more of three previous inspections, the form says.